- BioVersys achieved first patient first visit in the Phase 2b RIV-CARE study evaluating BV100.
- Progress represents a scheduled clinical milestone for the company's antibacterial pipeline.
- Further trial readouts and safety/efficacy data will serve as subsequent catalysts.
?? Positive AI Sentiment (+2.5 / 10)